Enzo Biochem, Inc. (ENZ)
- Previous Close
1.1500 - Open
1.1400 - Bid --
- Ask --
- Day's Range
1.1200 - 1.1765 - 52 Week Range
0.9900 - 1.5000 - Volume
66,868 - Avg. Volume
67,268 - Market Cap (intraday)
59.176M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1900 - Earnings Date Dec 13, 2024 - Dec 17, 2024
- Forward Dividend & Yield 0.40 (34.78%)
- Ex-Dividend Date Nov 15, 2024
- 1y Target Est
--
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
www.enzo.comRecent News: ENZ
View MorePerformance Overview: ENZ
Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENZ
View MoreValuation Measures
Market Cap
59.18M
Enterprise Value
10.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.83
Price/Book (mrq)
1.05
Enterprise Value/Revenue
0.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-81.73%
Return on Assets (ttm)
-7.44%
Return on Equity (ttm)
-14.59%
Revenue (ttm)
31.91M
Net Income Avi to Common (ttm)
-9.82M
Diluted EPS (ttm)
-0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
52.37M
Total Debt/Equity (mrq)
6.25%
Levered Free Cash Flow (ttm)
-18.95M
Research Analysis: ENZ
View MoreCompany Insights: ENZ
ENZ does not have Company Insights